
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Chicago-Recognition of combination drug therapy for selected patients with benign prostatic hyperplasia represents one of several key changes in clinical management embraced by AUA in the organization's first-ever clinical guidelines for BPH.





